Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the top high-conviction stocks to buy according to hedge funds. Deutsche Bank cut the price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 on June 2 while maintaining a Sell rating on the shares. The stock also received a rating update from BofA on May 12, with the firm cutting the price target on the stock to $515 from $520 and reiterating a Buy rating on the shares.

For additional reference, in its financial results for fiscal Q1, Intuitive Surgical, Inc. (NASDAQ:ISRG) reported that worldwide procedures for da Vinci and Ion combined grew around 17% compared to fiscal Q1 2025, with Da Vinci procedures growing approximately 16%, and Ion procedures growing approximately 39%. Revenue for the quarter came up to $2.77 billion, up 23% compared to $2.25 billion in the prior year period. The company also reported that it placed 431 da Vinci surgical systems, compared with 367 in fiscal Q1 2025.

Intuitive Surgical, Inc. (NASDAQ:ISRG) has an elaborate ecosystem of services and products that provide robotic-assisted surgical solutions and invasive care. Its products include the Ion Endoluminal and the Da Vinci Surgical systems.

While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.